Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1416212

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1416212

Chagas Disease: American trypanosomiasis Market

PUBLISHED:
PAGES: 25 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3500
PDF (2-5 Users)
USD 4200
PDF (Site License)
USD 5040
PDF (Enterprise License)
USD 6048

Add to Cart

Highlights:

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Report Scope:

The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.

Report Includes:

  • An overview of the global chagas disease (T. cruzi infection) market
  • Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
  • Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region
  • Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
  • Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals
  • Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed
  • Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies
  • Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses
Product Code: PHM282A

Table of Contents

Chapter 1 Introduction

  • Overview
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

  • History
  • Trypanosoma Cruzi
  • Vector and T. cruzi
  • Transmission Routes
  • Clinical Forms
  • Future Perspectives
  • Novel Drugs

Chapter 4 Chagas Disease by Drugs

  • Overview
  • Benznidazole
  • Toxicity of Benznidazole
  • Nifurtimox
  • Toxicity of Nifurtimox

Chapter 5 Chagas Disease by Diagnosis

  • Overview
  • Serology (Antibody Detection)
  • Molecular Testing

Chapter 6 Competitive Landscape

  • Competitive Analysis

Chapter 7 Company Profiles

  • BAYER AG
  • INSUD PHARMA

Chapter 8 Appendix: Acronyms

Product Code: PHM282A

List of Tables

  • Table 1 : Novel Drugs for Chagas Disease Treatment
  • Table 2 : Drugs for Chagas Disease
  • Table 3 : Bayer AG: Company Snapshot
  • Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
  • Table 5 : Bayer AG: News
  • Table 6 : Insud Pharma: Company Snapshot
  • Table 7 : Insud Pharma: News
  • Table 8 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Life Cycle of Trypanosoma Cruzi
  • Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
  • Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
  • Figure 3 : Bayer AG: Revenue Shares, by Region, 2022
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!